A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection

Retrospective data showed that when we administered ledipasvir/sofosbuvir (LDV/SOF) to patients with hepatitis B and C coinfection, there was a modest reduction in hepatitis B surface antigen (HBsAg). Therefore, we hypothesize that similar HBsAg reduction can be seen in hepatitis B virus (HBV) monoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Angie S., Nelson, Amy K., Ghosh, Alip, Kottilil, Shyamasundaran, Chua, Joel V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087219/
https://www.ncbi.nlm.nih.gov/pubmed/36045503
http://dx.doi.org/10.1002/jmv.28105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087219/
https://www.ncbi.nlm.nih.gov/pubmed/36045503
http://dx.doi.org/10.1002/jmv.28105

Ejemplares similares